The first national survey of antimicrobial use among dentists in Japan from 2015 to 2017 based on the national database of health insurance claims and specific health checkups of Japan

Akane Ono¹*, Masahiro Ishikane¹,2*, Yoshiki Kusama¹*, Chika Tanaka¹,², Sachiko Ono³, Shinya Tsuzuki¹, Yuichi Muraki⁴, Daisuke Yamasaki⁵, Masaki Tanabe⁵, Norio Ohmagari¹,2

¹ AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan, 2 Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan, 3 Department of Eat-loss Medicine, The University of Tokyo, Tokyo, Japan, 4 Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan, 5 Department of Infection Control and Prevention, Mie University Hospital, Mie, Japan

* These authors contributed equally to this work.
* stone.bagle@gmail.com

Abstract

Purpose
To counter the global health threat of antimicrobial resistance, effective antimicrobial stewardship programs are needed to improve antimicrobial use (AMU) among dentists in addition to physicians. This study aimed to investigate the nationwide epidemiology of AMU among Japanese dentists to facilitate the development of dentist-centered programs.

Methods
We conducted a retrospective population-based study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan to analyze the AMU among Japanese dentists between 2015 and 2017. AMU was quantified as the defined daily doses per 1,000 inhabitants per day (DID). The trends in dentist-prescribed AMU were examined according to antimicrobial category and administration route. We also compared outpatient oral AMU between dentists and physicians as well as between on-site and off-site dispensing.

Results
The DID values of dentist-prescribed AMU were 1.23 in 2015, 1.22 in 2016, and 1.21 in 2017. During this study period, outpatient oral antimicrobials comprised the majority (approximately 99%) of dentist-prescribed AMU, and cephalosporins were the most frequently prescribed antimicrobials (>60% of all antimicrobials). The DID values of outpatient oral AMU were 1.21 for dentists and 12.11 for physicians. The DID value for on-site dispensing.
Conclusions

Interventions that target dentists in Japan should focus on on-site dispensing of oral antimicrobials (especially cephalosporins) for outpatients. Further studies are needed to ascertain the underlying factors of oral cephalosporin prescriptions to guide the development of effective antimicrobial stewardship programs.

Introduction

The World Health Organization has advocated that each country develops a national action plan to counter the rising global health threat of antimicrobial resistance (AMR). Such plans include targeted reductions in antimicrobial use (AMU) within predetermined time frames and the promotion of antimicrobial stewardship programs (ASPs). Several countries have reported that dentists account for 7–11% of all AMU [1–6]. In the US, dentists constitute the second-leading prescribers of antimicrobials (10%) after physicians (80%) [7], with outpatient prescriptions forming the majority (59.1%) of antimicrobial-related expenditures [8]. Although AMU in dental practice is much lower than that of medical practice in the US, Germany, and England [1–3, 5, 6], a rise in dentist-prescribed AMU has been reported in Canada [4]. That study also suggested a need for ASPs that target dentists due to a propensity to unnecessarily prescribe antimicrobials for periapical abscesses and irreversible pulpitis, as well as their sluggish adoption of updated guidelines that stipulate the reduction of perioperative AMU for patients with valvular heart disease and prosthetic joints [4].

Japan’s National Action Plan on AMR from 2016 to 2020 showed that its national AMU was comparable to that of other industrialized countries in the EU [9]. However, Japan uses a much larger proportion of broad-spectrum antimicrobials (e.g., cephalosporins, macrolides, and fluoroquinolones) and a smaller proportion of narrow-spectrum agents (e.g., penicillin) than these other countries [9]. These trends can potentially contribute to the spread of AMR in Japan, and there is therefore a need to assess and control the use of broad-spectrum antimicrobials. Two studies with small sample sizes in limited settings have reported on the inappropriate use of antimicrobials by Japanese dentists [10, 11]. One of these studies found that over 80% of dentists prescribed prophylactic cephalosporins for dental procedures [10], and the other showed that dentists often prescribed antimicrobials post-procedurally despite limited supporting evidence for their effectiveness [11]. The design of ASPs should be informed by an understanding of current AMU trends, but no studies have explored the nationwide epidemiology of AMU among dentists in Japan.

Thus, we conducted a retrospective population-based study using data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) between 2015 and 2017 to investigate the epidemiology of AMU among Japanese dentists to support the development and implementation of effective ASPs.

Methods

Ethics statement

This study was approved by the ethics committee of the National Center for Global Health and Medicine (Approval Number: NCGM-G-002505-00), and was conducted in accordance with
the Declaration of Helsinki. Patient data were anonymized prior to analysis. The ethics committee waived the need for patient consent because the study did not deal with any personally identifiable information.

**Study design and data source**

This retrospective population-based study was conducted using NDB data from January 2015 to December 2017. In Japan, the national health insurance system provides universal coverage for all citizens and long-term residents. Insurance claims for almost all national health insurance–covered healthcare goods and services are collected and stored in the NDB after anonymization. From the NDB, we extracted all claims for antimicrobials that were prescribed by dentists during the study period. We only obtained aggregate data that did not include personally identifiable information, such as birth dates. In addition, the NDB only includes electronic claims data (without any paper-based claims). With the progression of data digitization, the proportion of electronic claims from dentists had steadily increased from 40% in 2011 to 96% in 2015 [12]. Therefore, we focused on data from 2015 to 2017 even though NDB data were available from 2011 onward. We also acquired data on antimicrobial prescriptions by physicians in 2016. The numbers of dentists and physicians were obtained from the National Surveys of Physicians, Dentists and Pharmacists published by the Ministry of Health, Labour and Welfare of Japan [13, 14]. The open data on physician- and dentist-prescribed AMU were acquired from the AMR Clinical Reference Center website [15].

Prescriptions were categorized into outpatient and inpatient prescriptions, and outpatient prescriptions were further sub-categorized into on-site and off-site dispensing. On-site dispensing was defined as antimicrobial prescriptions that are filled at the prescribing facility. In contrast, off-site dispensing referred to antimicrobial prescriptions that are filled at a third-party retail pharmacy, which allows the prescribing physician/dentist to prescribe any antimicrobial regardless of whether their facility has it in stock.

**Antimicrobial categories and use**

Antimicrobials were categorized based on the World Health Organization’s Anatomical Therapeutic Chemicals (ATC) Classification System and administration route (oral vs. parenteral). AMU was standardized as the defined daily dose, and the volume of use was quantified as the defined daily doses per 1,000 inhabitants per day (DID) [16–18]. The number of inhabitants was obtained from annual population estimates published by the Ministry of Internal Affairs and Communications of Japan [19]. We examined AMU according to the following ATC Level 4 categories: penicillins (ATC code: J01C), cephalosporins (J01DB/J01DC/J01DD/J01DE), macrolides (J01FA), fluoroquinolones (J01MA), and others (J01 excluding the aforementioned codes). Although the ATC code J01DI also includes cephalosporins (ceftobiprole medocaril, ceftaroline fosamil, and ceftolozane/β-lactamase inhibitor combination), these were not used in Japan during the study period. Accordingly, J01DI was sorted into the “others” category.

**Outcomes of interest and statistical analysis**

We first analyzed the annual trends in dentist-prescribed total AMU stratified by antimicrobial category and administration route between 2015 and 2017. Thereafter, we compared (i) oral AMU in the outpatient setting between dentists and physicians in 2016 (when AMU data from physicians were available) [15] and (ii) oral AMU in the outpatient setting between on-site and off-site dispensing among dentists in 2017. The patterns in oral AMU between dentists and physicians were compared using chi-square tests. Statistical significance was set at \( P < 0.05 \).
Results

Annual trends in total AMU among dentists stratified by antimicrobial category and administration route in 2015 to 2017

Table 1 shows the DID values of total AMU among dentists stratified by antimicrobial category. The DID values were 1.23 in 2015, 1.22 in 2016, and 1.21 in 2017. Cephalosporins accounted for the majority of antimicrobials with DID values (proportion of total antimicrobials) of 0.81 (65.6%) in 2015, 0.80 (65.2%) in 2016, and 0.77 (63.7%) in 2017. Over the study period, the DID values of penicillins gradually increased while those of cephalosporins slowly decreased. In contrast, the AMU trends for macrolides and fluoroquinolones were stable over time. The penicillins in Table 1 included antimicrobials with ATC codes J01CA, J01CE, and J01CR. The DID values of J01CA antimicrobials (which include amoxicillin) were 0.10 in 2015, 0.10 in 2016, and 0.12 in 2017. The DID values of J01FF antimicrobials (which include clindamycin) were 0.0017 in 2015, 0.0019 in 2016, and 0.0022 in 2017. Table 2 presents the DID values of total AMU among dentists stratified by administration route. In all three years, outpatient oral antimicrobials comprised the majority of dentist-prescribed AMU (approximately 99%).

Comparison of outpatient oral AMU between dentists and physicians in 2016

Table 3 shows the outpatient oral AMU for dentists (n = 104,533) and physicians (n = 319,480) in 2016. The DID values were 1.21 for dentists and 12.11 for physicians. In addition, dentists accounted for approximately 9.1% of the national outpatient oral AMU (i.e., outpatient oral AMU for both dentists and physicians). There were significant differences in the proportions of outpatient oral AMU between dentists and physicians (P < 0.001).

Table 1. Annual total antimicrobial use among dentists from 2015 to 2017 stratified by antimicrobial category.

|                | 2015    |         | 2016    |         | 2017    |         |
|----------------|---------|---------|---------|---------|---------|---------|
| Penicillins    | 0.10    | (8.0)   | 0.11    | (8.8)   | 0.13    | (10.3)  |
| Cephalosporins | 0.81    | (65.6)  | 0.80    | (65.2)  | 0.77    | (63.7)  |
| Macrolides     | 0.23    | (19.0)  | 0.30    | (18.7)  | 0.23    | (18.8)  |
| Fluoroquinolones| 0.067  | (5.4)   | 0.067   | (5.4)   | 0.066   | (5.4)   |
| Others         | 0.023   | (1.9)   | 0.023   | (1.9)   | 0.022   | (1.8)   |
| Total          | 1.23    |         | 1.22    |         | 1.21    |         |

Values are presented as defined daily doses per 1,000 inhabitants per day (% of total).

https://doi.org/10.1371/journal.pone.0244521.t001

Table 2. Annual total antimicrobial use among dentists from 2015 to 2017 stratified by administration route.

|                | 2015    |         | 2016    |         | 2017    |         |
|----------------|---------|---------|---------|---------|---------|---------|
| Outpatient oral administration | 1.213   | (99.0)  | 1.21    | (98.9)  | 1.20    | (98.9)  |
| Outpatient parenteral administration | <0.010 | (0.1)   | <0.010  | (0.1)   | <0.010  | (0.1)   |
| Inpatient oral administration | <0.010  | (0.5)   | <0.010  | (0.5)   | <0.010  | (0.5)   |
| Inpatient parenteral administration | <0.010 | (0.4)   | <0.010  | (0.4)   | <0.010  | (0.4)   |
| Total          | 1.23    |         | 1.22    |         | 1.21    |         |

Values are presented as defined daily doses per 1,000 inhabitants per day (% of total).

https://doi.org/10.1371/journal.pone.0244521.t002
Comparison of outpatient oral AMU between on-site and off-site dispensing among dentists in 2017

Table 4 shows the outpatient oral AMU for on-site and off-site dispensing among dentists in 2017. The DID values were 0.89 for on-site dispensing and 0.31 for off-site dispensing. In addition, on-site dispensing accounted for 74.2% of all outpatient oral AMU among dentists. Cephalosporins were the predominant antimicrobials in both on-site (DID: 0.60; 66.9% of outpatient oral AMU) and off-site (DID: 0.17; 54.1% of outpatient oral AMU) dispensing.

Discussion

This nationwide study of AMU among Japanese dentists found that the vast majority of their antimicrobial prescriptions were for oral antimicrobials in the outpatient setting (approximately 99%), and that cephalosporins were predominantly used (>60%). These results corroborate those of a previous cross-sectional questionnaire-based study on dentists at community clinics in Japan [20]. The frequent use of cephalosporins in Japan may be due in part to the active promotion of these antimicrobials by pharmaceutical companies. A study conducted in Nepal showed that the top-selling antimicrobials were those that were subjected to intensive promotional activities [21]. Although such promotional activities have since diminished in Japan, the situation was similar to that of Nepal as recently as 10 years ago. These activities may therefore have contributed to the high adoption rate of cephalosporins in Japan's medical facilities. In our previous analysis of AMU in 31 Japanese hospitals, we found that all the study hospitals had adopted the use of oral third-generation cephalosporins [22]. Furthermore, most of these cephalosporins were Japanese-origin drugs that are not commonly used outside of Japan [17]. The prevalent use of cephalosporins by Japanese dentists is in contrast to the utilization patterns in other countries [4, 5, 23–26]. For example, a national survey of German

Table 3. Comparison of outpatient oral antimicrobial use between dentists and physicians in 2016.

|                  | Dentists n = 104,533 | Physicians n = 319,480 |
|------------------|----------------------|------------------------|
| Penicillins      | 0.11 (8.7)           | 0.98 (8.1)             |
| Cephalosporins   | 0.79 (65.2)          | 2.80 (23.1)            |
| Macrolides       | 0.23 (18.9)          | 4.47 (36.9)            |
| Fluoroquinolones | 0.067 (5.5)          | 2.69 (22.2)            |
| Others           | 0.022 (1.8)          | 1.18 (9.7)             |
| **Total**        | **1.21**             | **12.11**              |

Values are presented as defined daily doses per 1,000 inhabitants per day (% of total).
There were significant differences in the proportions of oral antimicrobial use between dentists and physicians (\(P < 0.001\)).

https://doi.org/10.1371/journal.pone.0244521.t003

Table 4. Comparison of outpatient oral antimicrobial use between on-site and off-site dispensing among dentists in 2017.

|                  | On-site | Off-site |
|------------------|---------|----------|
| Penicillins      | 0.080 (9.0) | 0.042 (13.8) |
| Cephalosporins   | 0.60 (66.9) | 0.17 (54.1)  |
| Macrolides       | 0.15 (17.2) | 0.073 (23.9) |
| Fluoroquinolones | 0.047 (5.2) | 0.019 (6.1)  |
| Others           | 0.014 (1.6) | 0.006 (2.1)  |
| **Total**        | **0.89** | **0.31** |

Values are presented as defined daily doses per 1,000 inhabitants per day (% of total).

https://doi.org/10.1371/journal.pone.0244521.t004
dentists showed amoxicillin to be the most commonly prescribed antimicrobial (45.8% of total AMU in 2015) [5]. A Canadian study using a population-based prescribing database reported on the dominant use of amoxicillin (1.26 DID out of 1.59 DID; 79.2% of total AMU in 2013) [4]. Similar findings have also been reported in Kuwait [23] and Scotland [24]. In comparisons of antimicrobial prescription rates, amoxicillin was also found to be the dominant antimicrobial in the US (57% in 2015) [25] and Australia (64.3% in 2016) [26]. Our study also showed that the annual DID value of dentist-prescribed oral AMU was 1.21, which accounted for approximately 9.1% of the national outpatient oral AMU. This proportion was similar to that reported in other countries [4–6].

Although our study found that the AMU of Japanese dentists was lower than that of physicians, the former predominantly used cephalosporins, whereas the latter frequently used macrolides and fluoroquinolones in addition to cephalosporins. In general, the causal bacteria of odontogenic infections can be treated with penicillins or penicillin/β-lactamase inhibitor combinations, with a single dose recommended before a procedure. Therefore, it may be beneficial for dentist-centered ASPs to focus on the appropriate use of oral cephalosporins in outpatients. The 2011 version of Japan’s Guidelines for the Clinical Management of Infectious Diseases did not address odontogenic infections [27]. However, these were included in the 2014 version [28, 29] following the emergence of AMR as a major health threat. These guidelines recommend the use of penicillins, not cephalosporins, as first-line therapy for odontogenic infections [29]. Our analysis detected a slight increase in penicillin use accompanied by a minor decrease in cephalosporin use from 2015 to 2017, which may be indicative of a trend toward more appropriate AMU. A previous report suggested that dentists in Japan tend to follow the prescribing habits of more senior dentists without judicious consideration of current best practices [10]. However, we posit that the AMU among dentists will improve as the updated guidelines are increasingly adopted.

Our analysis showed that on-site dispensing accounted for 74.2% (DID: 0.89) of outpatient oral AMU among dentists, and that cephalosporins were the most frequently prescribed antimicrobials (66.9%). In Japan, approximately 80% of all dental facilities are privately owned and operated [30]. Our previous questionnaire-based study showed that the majority of private dental facilities are only able to provide on-site dispensing for two antimicrobials, one of which is frequently a cephalosporin [31]. We posit that the availability of two antimicrobials may be sufficient for most prophylactic or therapeutic applications in these facilities, even in cases where a patient is allergic to one of the antimicrobials. In consideration of these results, a potentially effective ASP for dentists may involve interventions to shift the use of cephalosporins to penicillins at private dental facilities. For example, antimicrobial prescribing has undergone a steady decline in England due to active interventions by the National Health Service, such as the release of antimicrobial stewardship messages that highlight the potential role of clindamycin in causing Clostridioides difficile infections [1]. Furthermore, the decline in antimicrobial prescribing is also expected to continue with the use of the Dental Antimicrobial Stewardship Toolkit [32]. This indicates that interventions aimed at dental facilities can improve antimicrobial prescription practices among dentists, and that standardized and intensive approaches may also be warranted in Japan.

This study has several limitations. First, the retrospective use of claims data means that we were unable to collect clinically relevant information regarding the prescriptions, such as patient and dentist characteristics, purpose of each prescription (therapeutic or prophylactic), and targeted diseases and procedures. Japan’s Guidelines for the Clinical Management of Infectious Diseases [29] and the Japanese Circulation Society’s 2017 Guidelines on the Prevention and Treatment of Infective Endocarditis [33] recommend the use of antimicrobials for infective endocarditis prophylaxis, which may represent one of the main reasons for
antimicrobial prescriptions by dentists. Nevertheless, we were unable to ascertain the specific reason for which each antimicrobial was prescribed. We are currently conducting a questionnaire-based epidemiological study to further investigate the purpose of antimicrobial prescriptions by dentists. Second, the data were collected only from the NDB, which did not include uninsured patients such as tourists. However, these individuals would only account for a very small portion of the total population. Despite these limitations, our study’s strength lies in the use of a national database that encompasses as much as 96% of the total population in Japan [12]. To the best of our knowledge, this is the first nationwide study of the epidemiology of AMU among Japanese dentists. In addition to dentists and physicians, AMU should also be examined in veterinarians as they act as both physicians and pharmacists in Japan and other countries. As the World Health Organization’s One Health approach recommends a holistic and multisectoral approach to AMR measures, there is an urgent need to implement effective ASPs for both human and veterinary medicine [34].

In conclusion, this study showed that dentist-prescribed AMU mostly involved oral antimicrobials for outpatients, and that cephalosporins were predominantly used. Dentists accounted for 9.1% of all outpatient oral AMU in Japan. There is a need for the development and implementation of dentist-centered ASPs that focus on oral cephalosporins for outpatients. Further studies are also needed to identify the factors associated with dentists’ prescription of oral cephalosporins in order to inform the development of more effective ASPs.

Acknowledgments
We thank all the staff of the AMR Clinical Reference Center for their support in establishing Japan’s National Action Plan on AMR from 2016 to 2020.

Author Contributions
Conceptualization: Masahiro Ishikane, Yoshiki Kusama, Chika Tanaka, Sachiko Ono, Norio Ohmagari.

Data curation: Masahiro Ishikane, Yoshiki Kusama, Chika Tanaka.

Formal analysis: Masahiro Ishikane, Sachiko Ono, Shinya Tsuzuki.

Funding acquisition: Norio Ohmagari.

Investigation: Akane Ono, Masahiro Ishikane, Yoshiki Kusama, Chika Tanaka, Yuichi Muraki, Daisuke Yamasaki, Masaki Tanabe.

Methodology: Akane Ono, Masahiro Ishikane, Yoshiki Kusama, Chika Tanaka.

Supervision: Yuichi Muraki, Daisuke Yamasaki, Masaki Tanabe, Norio Ohmagari.

Validation: Yoshiki Kusama, Chika Tanaka.

Writing – original draft: Akane Ono, Masahiro Ishikane.

Writing – review & editing: Yoshiki Kusama, Chika Tanaka, Sachiko Ono, Shinya Tsuzuki, Yuichi Muraki, Daisuke Yamasaki, Masaki Tanabe, Norio Ohmagari.

References
1. Thornhill MH, Dayer MJ, Durkin MJ, Lockhart PB, Baddour LM. Oral antibiotic prescribing by NHS dentists in England 2010–2017. Br Dent J. 2019; 227: 1044–50. https://doi.org/10.1038/s41415-019-1002-3 PMID: 31873263
2. Hicks LA, Taylor TH, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013; 368: 1461–2. https://doi.org/10.1056/NEJMc1212055 PMID: 23574140
3. Temhag A, Hellman J. More on U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013; 369: 1175–6. https://doi.org/10.1056/NEJMc1306863

4. Marra F, George D, Chong M, Sutherland S, Patrick DM. Antibiotic prescribing by dentists has increased Why? J Am Dent Assoc. 2016; 147: 320–7. https://doi.org/10.1016/j.adaj.2015.12.014 PMID: 26857041

5. Halling F, Neff A, Heymann P, Ziebart T. Trends in antibiotic prescribing by dental practitioners in Germany. J Cranio-Maxillofacial Surg. 2017; 45: 1854–9. https://doi.org/10.1016/j.jcms.2017.08.010 PMID: 28939205

6. Gross AE, Hanna D, Rowan SA, Bleasdale SC, Suda KJ. Successful implementation of an antibiotic stewardship program in an academic dental practice. Open Forum Infect Dis. 2019; 6: ofz067. https://doi.org/10.1093/ofid/ofz067 PMID: 30895206

7. Suda KJ, Roberts RM, Hunkler RJ, Taylor AH. Antibiotic prescriptions in the community by type of provider in the United States, 2005–2010. Journal of the American Pharmacists Association. 2016; 56: 621–6.e1. https://doi.org/10.1016/j.japh.2016.08.015 PMID: 27745794

8. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Matusiak LM, Schumock GT. Antibiotic Expenditures by Medication, Class, and Healthcare Setting in the United States, 2010–2015. Clinical Infectious Diseases. 2018; 66: 185–90. https://doi.org/10.1093/cid/cix773 PMID: 29020276

9. The Government of Japan. National Action Plan on Antimicrobial Resistance (AMR) 2016–2020. [cited 2020 Sep 18]. Available from: https://www.mhlw.go.jp/file/06-Seisakujuhou-10900000-Kenkoukyoku/0000138942.pdf

10. Yoshida K, Kodama Y, Isobe H, Yamada E, Nishikawa A, Takagi R. Survey of Antimicrobial Prophylaxis Agents and Surgical Site Infection Status Regarding Teeth Extraction in a Dental Outpatient Clinic. Japanese J Infect Prev Control. 2018; 33: 207–12. https://doi.org/10.4058/jssel.33.207

11. Kano Y, Tagashira Y, Kobayashi D, Honda H, Tani L. Dentists’ perceptions of antimicrobial use for dental procedures. Infect Control Hosp Epidemiol. 2019; 40: 1081–3. https://doi.org/10.1017/ice.2019.186 PMID: 31250785

12. Ministry of Health, Labour and Welfare of Japan. Situation in the prevalence of the claim submission via electronic devices (in Japanese). [cited 2020 Sep 18]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000099015.html

13. Ministry of Health, Labour and Welfare of Japan. Survey of Physicians, Dentists and Pharmacists 2016. [cited 2020 Sep 18]. Available from: https://www.mhlw.go.jp/english/database/db-hss/dl/spdp_2016.pdf

14. Ministry of Health, Labour and Welfare of Japan. Survey of Physicians, Dentists and Pharmacists 2016 (in Japanese). Ministry of Health, Labour and Welfare of Japan. [cited 2020 Sep 18]. Available from: https://www.mhlw.go.jp/jpkenkouyou/0000138942.pdf

15. AMR Clinical Reference Center. Antimicrobial Use Survey Based on the NDB.; 2018. [cited 2020 Sep 18]. Available from: http://amrcc.ncgm.go.jp/surveillance/010/NDB_Figure181030.pdf

16. Muraki Y, Yagi T, Tsuji Y, Nishimura N, Tanabe M, Niwa T, et al. Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009–2013). J Glob Antimicrob Resist. 2016; 7: 19–23. https://doi.org/10.1016/j.jgar.2016.07.002 PMID: 27973324

17. Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 2018; 24: 414–21. https://doi.org/10.1016/j.jic.2018.01.003 PMID: 29428666

18. Kusama Y, Ishikane M, Tanaka C, Kimura Y, Yumura E, Hayakawa K, et al. Regional variation of antimicrobial use in Japan from 2013–2016, as estimated by the sales data. Jpn J Infect Dis. 2019; 72 (5):326–329. https://doi.org/10.7883/yoken.JJID.2018.417 PMID: 31061356

19. Statistics Bureau of Japan. Result of the Population Estimates. [cited 2020 Sep 18]. Available from: http://www.stat.go.jp/english/data/jinsui2/2.html

20. Amari Y, Uehara Y, Watanabe Y, Inui A, Sugihara E, Yokokawa H, et al. Status of antimicrobial use among dentists in Japan. J Gen Hosp Med. 2014; 6: 8–15.

21. Koju P, Rousseau SP, Van der Putten M, Shrestha A, Shrestha R. Advertisement of antibiotics for upper respiratory infections and equity in access to treatment: a cross-sectional study in Nepal. J Pharm Policy Pract. 2020; 13(4). https://doi.org/10.1186/s40545-020-0202-1 PMID: 32110416

22. Kusama Y, Muraki Y, Mochizuki T, Kurai H, Gu Y, Ohmagari N. Relationship between drug formulary and frequently used cephalosporins, macrolides and quinolones in Japanese hospitals. J Infect Chemother. 2020; 26(2):211–215. https://doi.org/10.1016/j.jic.2019.08.013 PMID: 31543436

23. Salako NO, Rotimi VO, Adib SM, Al-Mutawa S. Pattern of antibiotic prescription in the management of oral diseases among dentists in Kuwait. J Dent. 2004; 32(7):503–509. https://doi.org/10.1016/j.dent.2004.04.001 PMID: 15304295
24. Roy KM, Bagg J. Antibiotic prescribing by general dental practitioners in the Greater Glasgow Health Board, Scotland. *Br Dent J*. 2000; 188(12):674–676. https://doi.org/10.1038/sj.bdj.4800574 PMID: 11022382

25. Durkin MJ, Hsueh K, Sallah YH, et al. An evaluation of dental antibiotic prescribing practices in the United States. HHS Public Access. *J Am Dent Assoc*. 2017; 148(12):878–886. https://doi.org/10.1016/j.adaj.2017.07.019 PMID: 28941554

26. Teoh L, Stewart K, Marino RJ, McCullough MJ. Current prescribing trends of antibiotics by dentists in Australia from 2013 to 2016. Part 1. *Aust Dent J*. 2018; 63(3):329–337. https://doi.org/10.1111/adj.12622 PMID: 29754452

27. The Japanese Association for Infectious Diseases, Japanese Society of Chemotherapy. The JAID/JSC Guide to Clinical Management of Infectious Diseases 2011. 2011 ed. (The Japanese Association for Infectious Diseases, ed.).

28. The Japanese Association for Infectious Diseases, Japanese Society of Chemotherapy. The JAID/JSC Guide to Clinical Management of Infectious Diseases 2014. 2014 ed. (The Japanese association for infectious diseases, ed.). [cited 2020 Sep 18]. Available from: https://ndlonline.ndl.go.jp/#/detail/R300000001-I025976383-00

29. Kaneko A, Aoki T, Ikeda F, Kawabe R, Satoh T, Tsumura N. The 2016 JAID/JSC guidelines for clinical management of infectious disease–Odontogenic infections. *J Infect Chemother*. 2018; 24: 320–4. https://doi.org/10.1016/j.jiac.2017.09.014 PMID: 29503229

30. Ministry of Health, Labour and Welfare of Japan. Survey of Static/Dynamic Survey of Medical Institutions and Hospital Report, 2018 (in Japanese). [cited 2020 Sep 18]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/iryosd/18/dl/02sisetu30.pdf

31. Koizumi R, Kusama Y, Ishikane M, Tanaka C, Ono A, Gu Y, et al. Cross-sectional study to clarify the status of antimicrobial prescribing at outpatient care among dentists. *Kansenshokaku Zasshi*. (in press)

32. Public Health England. Dental antimicrobial stewardship: toolkit—GOV.UK. Public Health England. Published 2016. [cited 2020 Sep 18]. Available from: https://www.gov.uk/guidance/dental-antimicrobial-stewardship-toolkit

33. Nakatani S. Guideline on Prevention and Treatment of Infective Endocarditis. *Circ J*. 2019; 83:1767–1809. https://doi.org/10.1253/circj.CJ-19-0549 PMID: 31281136

34. World Health Organization. Global Action Plan on Antimicrobial Resistance. Vol 10.; 2015. Accessed November 12, 2020. https://www.who.int/antimicrobial-resistance/global-action-plan/en/